Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol

Launched by RABIA HUSSAIN · Jun 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a special education program led by pharmacists, delivered over the phone or online, can help adults with type 2 diabetes better manage their blood sugar levels, understand their condition, take their medications as prescribed, and improve their overall quality of life. The program includes five short virtual sessions where a pharmacist talks with participants, in addition to the usual care they receive from their healthcare team. The study also wants to find out if patients find this kind of remote education helpful and easy to use.

Adults aged 18 to 65 who have type 2 diabetes with blood sugar levels above the recommended target (measured by a test called HbA1c greater than 7%) and who receive care at Ibrahim Bin Hamad Obaidullah Hospital in Ras Al-Khaimah may be eligible to join. Participants need to speak Arabic, have access to a phone or internet, and be willing to take part. If they join, they will be randomly assigned to either receive the pharmacist-led education sessions plus usual care or continue with their usual care alone. Before and after the program, participants will have simple blood tests and answer questions about their diabetes knowledge, medication habits, and quality of life. Some people in the education group may also be invited to share their thoughts about the program in interviews.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Patients diagnosed with uncontrolled type 2 diabetes (defined as glycated haemoglobin \[HbA1c\] \>7%) within the previous 12 months
• • Adults (18 to 65 years) of either gender
• • Prescribed at least one antidiabetic medication
• • Have access to either a telephone or a mobile phone
• • Treated in an outpatient facility in IBOH, RAK
• • Arabic-speaking patients
• • Patients who understand study information and are given written informed consent.
• Exclusion Criteria:
• • Under 18 years old
• • Pregnant ladies
• • Patients admitted to the emergency department
• • Patients with severe hepatic or renal dysfunction
• • Diagnosed with type 1 DM or diagnosed with gestational diabetes
• • Having vision or hearing impairments and psychological problems
• • Immunocompromised patients, e.g., organ transplants, AIDS, cancer patients, and patients on immunosuppressant therapy
• • Patients with no or limited access to either a telephone or mobile phone, as well as those without reliable internet access